Latest news with #Aurobindo
Business Upturn
13 hours ago
- Business
- Business Upturn
Nuvama bullish on Aurobindo Pharma, sees 15% profit CAGR through FY27
By Markets Desk Published on June 20, 2025, 07:30 IST Nuvama Institutional Equities has reiterated a 'Buy' call on Aurobindo Pharma, with a target price of ₹1,460, as it sees the stock poised for a strong recovery led by new product launches, capacity expansions, and normalization of regulatory and operational issues. The brokerage notes that Aurobindo has invested over ₹10,000 crore in recent years toward growth-oriented assets including its Pen-G API facility, injectable plants, and biologics and peptide capabilities. While these investments have temporarily diluted return ratios, Nuvama believes they position the company strongly for medium- to long-term growth, especially in high-margin, non-oral dosage categories. Key triggers that could unlock value in FY26–27 include: Resumption of production at its Pen-G unit , which could improve vertical integration and cost competitiveness. New launches in Europe from the company's Chinese facility. Ramp-up of injectables business through the Eugia-5 plant and normalization of supply issues from Eugia-3. Volume growth in oral solids, which continue to be the company's bread and butter in regulated markets like the US. Nuvama is building in a revenue CAGR of 7%, EBITDA CAGR of 8%, and PAT CAGR of 15% over FY25–27. Despite the recent recovery in pharma stocks, Aurobindo continues to trade at 13.9x FY27E EPS, which represents a 16% discount to its 5-year historical average valuation. This makes the stock attractive not only from a growth and margin recovery standpoint but also on relative valuation terms, especially considering that many of its operational headwinds now appear to be easing. Aurobindo has also stepped up its focus on specialty and complex generics, including biosimilars, peptides, and depot injections, which can provide earnings durability beyond FY27. The company's recent USFDA approvals and steady ANDA filings also indicate improving regulatory momentum. Nuvama's thesis remains that execution of these strategic pivots—especially monetization of recent capex—could drive a meaningful re-rating of the stock over the next 6–8 quarters. Ahmedabad Plane Crash Markets Desk at
The Print
2 days ago
- Politics
- The Print
Savarkar severely criticised RSS for its ‘purely cultural' orientation
It is also true that during the nineteenth century, a new middle class emerged in India, which initiated religious reform movements in the country. Many Hindu reformers underlined that the lack of unity in the religion made it vulnerable and they began to consider a version of modernity with 'indigenous' (Hindu Brahminical) roots. The Arya Samaj established by Dayanand Saraswati and the 'Sanatana Dharma Sabha' started the cow protection movement. In 1882, Dayanand Saraswati formed the first 'Gaurakshini Sabha' (Cow Protection Organization) in Punjab. It later grew in many urban centres and the cow became a symbol of unification.6 It also enhanced the view, which considered Muslims and Christians as outsiders, while cow-worshipping Hindus were glorified as the original inhabitants of India. It could be argued this was the inception of religious nationalism in India. It is important to note that scholars like Jyotirmay Sharma have differentiated between the 'soft and hard version' of Hindutva. He includes thinkers like Dayanand Saraswati and Swami Vivekananda in the former category, and V.D. Savarkar and M.S. Golwalkar, in the latter.4 A. Raghuramraju, on the other hand, questioned this kind of classification and tendency to link social reformers with the idea of Hindutva. It is true that Vivekananda and Dayanand Saraswati advocated Indian traditions and used them to criticize superstitions and belief systems of the time but they used Hinduism, rather than Hindutva, to propagate their ideas of humanism. The basic idea behind this argument is that Hindutva started with the writings of Savarkar who differentiated between Hinduism and Hindutva. There are different kinds of analyses regarding the historical background of the emergence of the Hindu right wing, particularly the RSS in India. Scholars like Walter K. Anderson, Sridhar Damle, Bruce Graham, Thomas Bloom Hansen and Christophe Jaffrelot, posit the beginning of Hindutva politics in the 1920s. Other scholars like Partha Chatterjee, Vinay Lal, Ashis Nandy and Tapan Roychaudhuri underline that religious politics emerged as an integral part of nineteen century modern nationalist identity and blossomed in the first half of the twentieth century. For Aurobindo and Bankim Chandra Chatterjee, Hindu religious values were located at the centre of their idea of nationalism. For Aurobindo, nationalism was a religion and he emphasized that 'Indians were weak and unmanly and therefore required the 'Kshatriya' impulse; they had grown feeble and had to appropriate the 'shakti' of science.' Bankim wrote 'Bande Matram', which became the most important slogan of the Indian freedom struggle. In his three historical novels—Anandmath, Devi Chaudhurani and Sitaram—he presented the theme of Hindu–Muslim antagonism. These thinkers focused on Hindu traditions and values to develop their notion of nationalism. Most of them also vociferously criticized the negative aspects of Hindu society and only Bankim (in his later writings) presented a clear picture of the antagonism between Hindus and Muslims. Since they emphatically focussed on Hindu values, they became the icon of Hindutva politics, which emerged more systematically through the writings of Vinayak Damodar Savarkar and the formation of the RSS. Savarkar (1883–1966) presented a systematic idea of Hindutva in his book Hindutva: Who is a Hindu, first published in 1923. He differentiated between Hinduism and Hindutva. He argued that he coined the word Hindutva to describe the political philosophy of the Hindu people, and Hinduism was only one aspect of Hindutva. The term Hinduism excluded other religions of the land of Saptasindhu (the land of the seven rivers)—Buddhism, Jainism and Sikhism. At the beginning of Hindutva: Who is a Hindu, Savarkar defines a Hindu as a, …person who regards this land of BHARATVARSHA, from the Indus to the Seas of his Father-Land as well as his Holy-Land that is the cradle land of his religion. To the converted Christians and Muslims, the Hindustan is the Fatherland as to any other Hindu. Yet it is not to them a 'Holy Land' too. Their holy land is in Arabia or Palestine. Their mythology and Godmen, ideas, and heroes are not the children of this soil. Their names and outlooks smack of a foreign origin, so their love is divided. Savarkar most explicitly presented the notion of Hindutva and created 'otherness' for the followers of Islam and Christianity. The members of both communities are outside the boundaries of the 'Hindu nation' and Savarkar primarily focused on the antagonistic relations between Hindus and Muslims locked in a life-and-death battle for centuries. He cherished a nationalism based on the Hindu religion and the Hindu culture. As a propagator of Hindutva ideology, Savarkar underlines concerns about the impossibility of the coexistence of Hindus and Muslims. He accused Indian Muslims of being anti-Hindu and anti-India, with extraterritorial allegiance. Dr Keshav Baliram Hedgewar (1889–1940), who was an admirer of Sarvarkar's ideas, established the RSS in 1925, with the help of many like-minded people, including Savarkar's brother. The aim was to establish an organization to work for the awakening of Hindus for their religious interest and to serve the motherland. Indeed, like Savarkar, Hedgewar was also against the Gandhian idea of non-violence and felt that Gandhi's ideas were making Hindus weak and they benefitted Muslims. As a Congress worker, Hedgewar participated in the Non-cooperation Movement but felt cheated when Gandhi called it off after the Chauri Chaura incident of February 1922.13 Further, the Moplah riots and other communal incidents affected him and he realized that to protect the interests of the Hindus, a separate organization was necessary. Savarkar's ideas influenced Hedgewar, but he was very cautious about protecting the structure of the RSS. Hence, as RSS chief (sarsanghchalak), he never participated in any activity, which could create suspicion in the minds of the colonial rulers about the work of the RSS. Even when he participated in the Civil Disobedience Movement and went to jail, he handed over the responsibility of the sarsanghchalak to another swayamsevak (volunteer). It is noteworthy that Savarkar severely criticized the RSS for its 'purely cultural' orientation. He publicly stated that '[t]he epitaph for the RSS volunteer will be that he was born, he joined the RSS and he died without accomplishing anything.' This excerpt from Kamal Nayan Choubey's 'Adivasi or Vanvasi: Tribal India and the Politics of Hindutva' has been published with permission from Penguin Random House India.
News18
3 days ago
- Business
- News18
Donald Trump Says Pharma Tariffs 'Coming Soon'; Indian Drug Stocks Fall Up To 4%
Last Updated: US Pharma Tariffs: Granules India becomes the top loser falling up to 4%, while Aurobindo, Natco and Lupic was down 3% each. US President Donald Trump on June 17 said tariffs on the pharmaceutical sector are 'coming soon". Following comments, which Trump made while speaking to reporters on board the Air Force One, India's pharma stocks declined up to 4%. The Nifty Pharma index declined as much as 2.5% following the Trump comments. Granules India became the top loser falling up to 4%, while Aurobindo, Natco and Lupic was down 3% each. This isn't the first warning — back in April, after imposing reciprocal tariffs on 60 countries (excluding pharma at the time), Trump had hinted that pharma tariffs would come in at 'never seen before" levels and were under active review. 'Pharma tariffs are going to come in at levels you haven't really seen before. We are looking at pharmaceuticals as a separate category. We will be announcing that sometime in the near future, and not too distant future. It's under review right now," Trump had said back in April. The US Commerce Department is currently investigating pharma imports under Section 232, which evaluates the impact of imports on national security. If such tariffs are imposed and companies are unable to pass on the cost, analysts at Citi estimate Indian firms with high exposure to the US generics market could see a 9%-12% one-time hit to their Ebitda.
Business Upturn
28-05-2025
- Business
- Business Upturn
Aurobindo Pharma shares fall over 2% after Citi maintains ‘Sell' rating, cuts target price to Rs 1,100
By Aman Shukla Published on May 28, 2025, 10:08 IST Aurobindo Pharma shares fell over 2% after Citi maintained a 'Sell' rating and lowered its target price to ₹1,100. Citi expressed concerns about flattening growth in the US market and rising margin pressures ahead. As of 10:06 AM, the shares were trading 2.12% lower at Rs 1,165.90. In Q4FY25, Aurobindo reported a 10.6% year-on-year revenue increase to ₹8,382 crore, but net profit slightly dipped 0.5% to ₹902.8 crore. Citi highlighted that the company's adjusted EBITDA was around 5% below expectations. Excluding the $40–60 million contribution from gRevlimid, the baseline EBITDA margin stood at 18.5%, down 100 basis points compared to last year, despite a one-time ₹1,000 crore cost benefit. Management's outlook was described as underwhelming, projecting only high single-digit revenue growth and no significant improvement in injectables for FY26. Citi pointed out that although the US business saw 10% volume growth in FY25, signs of flattening sales and the removal of gRevlimid from the product mix may pressure margins over the next few quarters. Due to these factors, Citi cut its FY26–27 earnings per share estimates by 8%, indicating cautious sentiment around Aurobindo's near-term prospects. Investors should watch the company's US market performance closely as margin risks remain a key concern. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Time of India
27-05-2025
- Business
- Time of India
Aurobindo Pharma shares in focus after Q4 profit dips marginally to Rs 903 cr
Aurobindo Pharma shares are likely to be in focus on Tuesday after the Hyderabad-based drug manufacturer reported a marginal dip in its consolidated net profit for the March 2025 quarter. The company posted a profit after tax (PAT) of Rs 903 crore in Q4FY25, slightly lower than Rs 907 crore reported in the same quarter of the previous fiscal. Despite the minor decline in bottom-line performance, Aurobindo's revenue from operations rose to Rs 8,382 crore in the March quarter, up from Rs 7,580 crore in the year-ago period, indicating robust topline growth. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More For the full year ended March 31, 2025, the company delivered a 10% year-on-year increase in PAT at Rs 3,484 crore, compared to Rs 3,169 crore in FY24. Annual revenue also grew significantly to Rs 31,724 crore, up from Rs 29,002 crore the previous year. "We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. Live Events The drug firm's European operations continue to perform exceptionally well, moving steadily towards the USD 1 billion revenue milestone, Reddy added. Also read: EQT firm Sagility B.V. to offload up to Rs 2,671 crore stake in Sagility India via offer for sale Aurobindo Pharma share price history Over the past year, Aurobindo Pharma's stock has declined by 4.51%. The year-to-date (YTD) performance shows a drop of 12.73%, while the six-month return stands at a negative 4.05%. In contrast, the stock gained 9.06% over the last three months. However, it has slipped 3.16% in the past month. Aurobindo Pharma shares closed 1.4% lower at Rs 1,179.35 on the BSE on Tuesday. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
